National Blood Donor Week - Héma-Québec issues reminder about the importance of summer blood donations Français
Although donation bookings often slow down in summer when the weather gets nice and everyone goes on vacation, the need for blood remains critical all throughout the year. Every day, 1,000 donations are needed to meet the needs of hospitals across the province.
This National Blood Donor Week, Héma-Québec would also like to thank its donors, volunteers and staff for the essential work they do every day of the year.
Your first donation is easier than ever!
A number of donation eligibility criteria were relaxed last year to allow more people to donate. For example, people who spent time in France or the United Kingdom in the 1980s and 1990s were previously excluded due to risks related to variant Creutzfeldt-Jakob disease (vCJD). They are now eligible to donate, along with a greater number of people with diabetes. Another change was the adoption of gender-neutral questionnaires in 2022, which have helped a more sexually diverse range of people make donations.
Several blood drives take place each week throughout Québec, and appointments can be booked at different times at one of Héma-Québec's donation centres. Additionally, to improve the donation experience and offer more flexibility, Héma-Québec recently extended operating hours at several donation centres in Greater Montréal: facilities in Brossard, Laval, Montréal, Kirkland and Saint-Bruno are now open until 8:30 p.m., Monday to Friday, and are also open on weekends.
You can book an appointment online or by calling 1-800-343-7264 (SANG). If you want to make sure you are eligible to donate before coming in, visit Héma-Québec's website or call Donor Services at 1-800-847-2525.
About Héma-Québec
Héma-Québec's mission is to efficiently meet the Québec population's needs for blood and other high-quality biological products of human origin. Héma-Québec has over 1,900 employees, more than 200,000 donors of blood, stem cells, mother's milk and human tissues, as well as thousands of blood drive volunteers. Every year, Héma-Québec delivers nearly 800,000 biological products of human origin to Québec's hospitals in order to meet patients' needs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
13 hours ago
- Cision Canada
OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients
OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease 1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO ® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients. 1 OXLUMO is the first therapy for PH1 approved in Canada, and among the first medications to be included on the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases. The common list was developed to help patients with rare diseases have access to treatments as early as possible. PH1 is an ultra-rare and debilitating genetic disease of the liver characterized by oxalate overproduction. 2 Oxalate is an end-product of metabolism and high levels of it are toxic because it cannot be broken down by the human body. Oxalate overproduction results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones, nephrocalcinosis (renal deposition of calcium oxalate crystals), progression to kidney failure, and systemic organ dysfunction. 2 "Funding OXLUMO through the National Strategy for Drugs for Rare Diseases provides a new treatment option for people diagnosed with this debilitating, genetic disease – many of whom are infants and children," said Colleen Coxson, Country General Manager, Alnylam Canada ULC. "I want to congratulate the Canadian government for prioritizing access to therapies for those living with rare conditions, as there are often very limited options for patients." There are several types of primary hyperoxaluria (PH), however, PH1 is the most common and the most severe form, accounting for 70 to 80 per cent of all PH cases. 3 PH1 affects approximately four individuals per million, with some regions – such as the Middle East and North Africa – having a higher genetic prevalence. 4 Symptom onset ranges from early infancy to sixty years of age, with the median age being four to six years. 4 The remainder of affected cases present in adulthood with 20 to 50 per cent presenting late stages of chronic kidney disease when diagnosed. 4 "This funding decision marks a major step forward in the management of hyperoxaluria type 1, offering hope to patients of all ages living with this ultra-rare genetic condition," said Dr. Vladimir Belostotsky, Division Head for Pediatric Nephrology at McMaster Children's Hospital. "The medication has been shown to effectively lower urine oxalate levels, reducing the burden that leads to severe clinical symptoms." The positive recommendation for reimbursement was supported by results of the ILLUMINATE clinical studies, including ILLUMINATE-A: a randomized, double-blind, placebo-controlled clinical study in patients six years and older with PH1, ILLUMINATE-B: a single-arm clinical study in patients less than six years of age with PH1 1 and ILLUMINATE-C: a single-arm trial in patients of all ages with advanced PH1, including patients on dialysis. 5 The ILLUMINATE-A study showed that OXLUMO met its primary endpoint, evidenced by a 53 per cent mean reduction in urinary oxalate, and a 65 per cent mean reduction in urinary oxalate relative to baseline. 1 In ILLUMINATE-B, OXLUMO demonstrated a 72 per cent mean reduction in spot urinary oxalate:creatinine ratio from baseline to month six (averaged from months three to six), meeting its primary endpoint. 1 In ILLUMINATE-C, OXLUMO met its primary endpoint, demonstrating a 33% least squares (LS) mean reduction in plasma oxalate (POx) levels in patients not on dialysis (Cohort A) and a 42% LS mean reduction in POx levels in patients on hemodialysis (Cohort B) from baseline to month six. 6 About OXLUMO ® (lumasiran) 1 OXLUMO ® (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) in the liver to deplete the production of the glycolate oxidase (GO) enzyme. By silencing HAO1 and depleting the GO enzyme through RNA interference, OXLUMO in turn reduces the amount of oxalate that is produced. This process helps address the root cause of the rare, genetic disease since an overproduction of urinary and plasma oxalate levels is the underlying cause of PH1. About Primary Hyperoxaluria Type 1 (PH1) PH1 is an ultra-rare genetic disease that is characterized by oxalate overproduction in the liver, causing renal damage. Renal damage is caused by a combination of tubular toxicity from oxalate, calcium oxalate deposition in the kidneys, and urinary obstruction by calcium oxalate stones. PH1 is associated with a progressive decline in kidney function, which exacerbates the disease as the excess oxalate can no longer be effectively excreted, resulting in subsequent accumulation and deposition of oxalate in bones, eyes, skin, and heart, leading to severe illness and death. Management options to date have been limited to hyperhydration, crystallization inhibitors and, in a minority of patients with a specific genotype, pyridoxine (vitamin B6). These measures only delay the inevitable progression to kidney failure and the need for intensive dialysis as a bridge to a dual or sequential liver/kidney transplant. Other impacts of the disease include: infants often fail to thrive, meaning they are weak and not growing or developing at a normal rate. 7 Affected children frequently face developmental challenges, with social barriers and the requirement of accommodations to be made at school to meet their special medical needs. 6 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made.5 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its " Alnylam P 5 x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Canada is headquartered in Mississauga, Ontario with established operations since June 2018.
Cision Canada
15 hours ago
- Cision Canada
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
TORONTO, July 2, 2025 /CNW/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization. This approval marks a key milestone for Apotex, introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016, and reflecting the Company's commitment to expand its biologics portfolio and execution of its Journey of Health strategy. "With Aflivu, we're expanding affordable treatment options for Canadians affected by retinal diseases," said Raymond Shelley, President, Apotex Canada. "Apotex continues to deliver innovative, patient-focused solutions across our growing portfolio of brands, biosimilars, generics and consumer health products." "The approval of Aflivu represents a positive advancement in ophthalmic care," said Dr. Bernard R. Hurley, BSc, MD, FRCSC, Assistant Professor at the University of Ottawa Eye Institute. "Biosimilars, supported by clinicians, regulators, and manufacturers, have the potential to transform the treatment landscape for retinal diseases, preserving vision and providing quality, cost-effective care for countless Canadians." "In clinical practice, having access to a broader range of therapeutic options can empower physicians to tailor care to individual patients' needs," said Dr. Ghassan Cordahi, MD, FACS, Assistant Clinical Professor, Faculty of Medicine, Department of Ophthalmology, Université de Montréal. "Aflibercept has been a cornerstone in managing retinal diseases, and the introduction of Aflivu offers a more affordable alternative without compromising quality." Aflivu joins Apotex's successful biosimilar portfolio, which includes Grastofil® (filgrastim), Lapelga® (pegfilgrastim), and Bambevi® (bevacizumab). About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Cision Canada
17 hours ago
- Cision Canada
LUNG CANCER CANADA ANNOUNCES NEW PRESIDENT DR. ROSALYN JUERGENS - A BOLD VISION FOR THE FUTURE ROOTED IN CARE, COLLABORATION, AND IMPACT Français
TORONTO, July 2, 2025 /CNW/ - Lung Cancer Canada (LCC) is pleased to announce the appointment of Dr. Rosalyn Juergens as its new President, effective June 27, 2025. A highly respected medical oncologist, clinical researcher, and long-time member of LCC's Medical Advisory Committee, Dr. Juergens brings a deep understanding of patient care and a bold vision for continued progress across research, support, awareness, and advocacy. Dr. Juergens succeeds Dr. Stephanie Snow, whose impactful leadership since 2021 helped shape Lung Cancer Canada into a more national, connected, and equity-focused organization. During her tenure, LCC expanded its presence across Canada, deepened engagement in Quebec, and strengthened the voice of lung cancer patients in research, education, and public policy. "Serving as President of Lung Cancer Canada has been one of the most meaningful chapters of my life," said Dr. Stephanie Snow. "Together, we built new partnerships, expanded our reach, and worked to ensure that no one facing lung cancer is left behind. Rosalyn is the right leader to carry this work forward — a trusted colleague, brilliant clinician, and fierce advocate who will take Lung Cancer Canada to even greater heights." Dr. Juergens has been part of the Lung Cancer Canada family for over a decade, serving as a trusted clinical advisor and patient advocate. She brings cross-border healthcare experience from both Canada and the U.S. and has seen firsthand how system-level gaps – in screening, biomarker testing, treatment access, and clinical trial availability – affect patient outcomes. "Lung Cancer Canada has become a powerful voice for change — and now we must stretch even further," said Dr. Rosalyn Juergens. "As President, I'm committed to building on the progress we've made by working in partnership, with patients, caregivers, clinicians, and researchers, to deliver the care, access, and hope every Canadian with lung cancer deserves." As the only national charity in Canada exclusively dedicated to lung cancer, Lung Cancer Canada remains focused on delivering across its four core pillars: patient support, public awareness, research investment, and advocacy. Under Dr. Juergens' leadership, advocacy will continue to grow — not as a standalone initiative, but as an integrated force across all of LCC's work. This includes advancing five core priorities: Increasing survivorship through equitable access to screening Breaking down barriers to timely biomarker testing Ensuring faster access to the most effective treatments Boosting investment in lung cancer research Expanding access to clinical trials across all regions "I'm so pleased to welcome Dr. Juergens as our new President," said Shem Singh, Executive Director of Lung Cancer Canada. "This is a reaffirmation of who we are and the mission that drives us. Dr. Juergens brings the urgency, insight, and compassion this moment calls for. I'm excited for what's ahead: a chapter grounded in bold ideas, strong partnerships, and meaningful impact across the lung cancer community." Dr. Snow will remain an active member of Lung Cancer Canada's Board of Directors and will lead the organization's Fall 2025 National Policy Series, continuing to shape LCC's work in health system equity and patient access. Each President of Lung Cancer Canada has left a lasting mark — strengthening its voice, expanding its reach, and guiding the organization through transformative growth. With Dr. Juergens at the helm, Lung Cancer Canada enters a new chapter rooted in partnership, progress, and possibility. A public Q&A with Dr. Juergens will be hosted later this summer, and an upcoming episode of the Lung Cancer Voices podcast will feature a candid conversation between Dr. Juergens, Dr. Snow, and past Presidents Dr. Natasha Leighl and Dr. Paul Wheatley-Price. About Lung Cancer Canada Lung Cancer Canada is the only Canadian charity solely dedicated to supporting and advocating for those affected by lung cancer. As the leading national resource, Lung Cancer Canada provides support, trusted education, and strong advocacy to ensure patient voices shape healthcare decisions and treatment access. Lung Cancer Canada also champions research, funding innovation to improve outcomes and advance care. Through these efforts, Lung Cancer Canada empowers the lung cancer community while driving meaningful change. To learn more:
